UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

By L. Iyer, Soma Das, L. Janisch, Ming Wen, J. Ramírez, T. Karrison, G. Fleming, E. Vokes, R. Schilsky, M. Ratain. The Pharmacogenomics Journal, 2002

723 citations recorded by the source corpus.

Subfields: Molecular Biology, Pediatrics, Perinatology and Child Health, Pharmacology

View Paper: https://www.semanticscholar.org/paper/9bb3e4c5b9d2a7b7c8b3b7bdea4a4ffd8875fd7e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Hochster
2. A. Benson
3. D. Schrag
4. A. Venook
5. D. Niedzwiecki
6. H. Lenz
7. M. Bertagnolli
8. J. Meyerhardt

Citations in the corpus

• Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial (2017, background): “either crossed over to or continued with bevacizumab beyond tumor progression.(15) Twelve percent of patients”